Cefozopran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cefozopran
Accession Number
DB13667
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • céfozopran
  • cefozoprán
  • cefozopranum
Product Ingredients
IngredientUNIICASInChI Key
Cefozopran hydrochloride060I5C0GRC113981-44-5NTJHUKMPVIFDNY-XFDPNJHTSA-N
Categories
UNII
1LG87K28LW
CAS number
113359-04-9
Weight
Average: 515.52
Monoisotopic: 515.079407031
Chemical Formula
C19H17N9O5S2
InChI Key
QDUIJCOKQCCXQY-WHJQOFBOSA-N
InChI
InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
IUPAC Name
1-{[(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(methoxyimino)acetamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}imidazo[1,2-b]pyridazin-1-ium
SMILES
[H][C@]12SCC(C[N+]3=C4C=CC=NN4C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=NSC(N)=N1)C([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcenocoumarolCefozopran may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenCefozopran may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Acetylsalicylic acid.
AlprazolamCefozopran may decrease the excretion rate of Alprazolam which could result in a higher serum level.
AmikacinThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Amikacin.
AmlodipineCefozopran may decrease the excretion rate of Amlodipine which could result in a higher serum level.
AmoxicillinCefozopran may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
AmphetamineCefozopran may decrease the excretion rate of Amphetamine which could result in a higher serum level.
AmpicillinCefozopran may decrease the excretion rate of Ampicillin which could result in a higher serum level.
ApramycinCefozopran may increase the nephrotoxic activities of Apramycin.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01052
KEGG Compound
C11203
ChemSpider
7845546
ChEBI
3502
ChEMBL
CHEMBL1276663
Wikipedia
Cefozopran
ATC Codes
J01DE03 — Cefozopran

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.024 mg/mLALOGPS
logP-0.81ALOGPS
logP-4.3ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)2.74ChemAxon
pKa (Strongest Basic)0.074ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area184.11 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity147.37 m3·mol-1ChemAxon
Polarizability47.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Pyridazines and derivatives / N-substituted imidazoles / Thiadiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids / Azetidines / Carboxylic acid salts
show 13 more
Substituents
Cephalosporin / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / Meta-thiazine / Pyridazine / N-substituted imidazole / Tertiary carboxylic acid amide / Thiadiazole / Azole / Heteroaromatic compound
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin (CHEBI:3502)

Drug created on June 23, 2017 14:46 / Updated on August 02, 2018 06:56